Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Healthcare Xenpozyme Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C24670-A

    Acid Sphingomyelinase Deficiency (ASMD) — Xenpozyme Coverage

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C24670-A alerts

    Get alerted when Policy C24670-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage of intravenous Xenpozyme (olipudase alfa-rpcp) for adult and pediatric members with acid sphingomyelinase deficiency, limited to non-central nervous system manifestations and subject to diagnostic, clinical, specialist, and dosing documentation requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyAcid Sphingomyelinalase Deficiency (ASMD) — Xenpozyme Coverage
    Policy CodePolicy C24670-A
    Change TypeAnnual review — no material coverage changes
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit diagnostic confirmation, non-neurologic treatment goals, and current weight, height, and BMI for Xenpozyme prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The review history reports revisions to required medical information, continuation of therapy, duration of approval, contraindications or exclusions, discontinuation, and other special considerations.

    The review history reports revisions to available dosage forms and references.

    The review history reports revisions to coding and billing information and references.

    12 monthsInitial authorization
    12 monthsContinuation authorization
    3 mg/kg q2w

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maintenance dose
    Non-CNS onlyTreatment scope
    Black box warningSafety alert

    Coverage Criteria

    Initial Therapy Criteria

    Covered when ALL of the following applicable criteria are met:

    Initial therapy requirements

    • The member has a documented diagnosis of acid sphingomyelinase deficiency (ASMD) type A/B or type B, also known as Niemann-Pick disease.
    • Diagnostic confirmation

      • Acid sphingomyelinase enzyme deficiency is confirmed.
      • The diagnosis is confirmed by genetic testing of the SMPD1 gene.
    • Xenpozyme is not being used to treat neurologic manifestations, if present.
    • Individualized therapeutic goals are documented based on non-neurologic baseline symptoms, overall health, and quality of life.

      Examples include hepatosplenomegaly, liver and spleen volume, pulmonary function, platelet count, and pediatric height z-scores. Documentation is required.

    • Current dosing weight, weight, height, and body mass index (BMI) are documented.Within the last 30 days

      For BMI greater than 30, dosing must be based on adjusted body weight.

    • Xenpozyme is prescribed by or in consultation with a qualified specialist experienced in ASMD or related enzyme deficiency disorders.

      Qualified specialists include a board-certified geneticist, hematologist, pulmonologist, hepatologist, pediatric metabolic specialist, or physician experienced in ASMD, Niemann-Pick disease, or enzyme deficiency disorders. Consultation notes are required when prescribed in consultation.

    Continuation Therapy Criteria

    Covered for continuation when ALL of the following criteria are met:

    Continuation therapy requirements

    • The prescriber attests, or clinical review finds, no evidence of intolerable adverse effects or drug toxicity, including severe hypersensitivity reactions such as anaphylaxis.
    • Documentation shows a positive clinical response demonstrated by low disease activity and/or improvement in the condition's signs and symptoms.

      Examples include improvement in liver and spleen volume, pulmonary function, platelet count, and pediatric height z-scores.

    • Current weight, height, and body mass index (BMI) are documented.Within the last 30 days

      For BMI greater than 30, dosing must be based on adjusted body weight.

    Xenpozyme (olipudase alfa-rpcp) is covered for the labeled treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. Treatment intended for neurologic manifestations, or any other use outside the labeled indication, is considered experimental or investigational and follows Molina’s Off-Label policy.

    Initiation or dose escalation during pregnancy is not recommended because elevated sphingomyelin metabolite levels may increase the risk of fetal malformations. Female patients of reproductive potential should be counseled to use effective contraception during treatment and for 14 days after the last dose.

    Coding and Dosing Reference

    HCPCS CodeHCPCS
    J0218Injection, olipudase alfa-rpcp, 1 mg
    Acid sphingomyelinase activity
    Diagnostic thresholdAcid sphingomyelinase activity less than 10% of the control sample
    Acceptable specimensPeripheral blood leukocytes or cultured skin fibroblasts
    Clinical interpretationActivity below the threshold demonstrates acid sphingomyelinase deficiency
    Current dosing measurements
    Dosing weightCurrent dosing weight must be documented
    WeightCurrent weight must be documented
    Height

    Provider Requirements and Review Risks

    Prior Authorization

    Initial Authorization Requirements

    For initial authorization, submit documentation supporting medically necessary treatment of ASMD type A/B or type B, required diagnostic confirmation, non-neurologic treatment goals, current dosing measurements, qualified prescriber involvement, and the applicable dosing regimen.

    • Documented diagnosis of acid sphingomyelinase deficiency (ASMD) type A/B or type B, also known as Niemann-Pick disease.
    • Diagnosis confirmed by acid sphingomyelinase enzyme deficiency or SMPD1 genetic testing; peripheral blood leukocyte or cultured skin fibroblast ASM activity below 10% of the control sample demonstrates deficiency.
    • Document that Xenpozyme is not being used to treat neurologic manifestations, if present.
    • Provide individualized therapeutic goals based on non-neurologic baseline symptoms, such as hepatosplenomegaly, liver and spleen volume, pulmonary function, platelet count, pediatric height z-scores, overall health, and quality of life.
    • Submit current dosing weight, weight, height, and BMI obtained within the last 30 days. Use actual body weight when BMI is 30 or less and adjusted body weight when BMI exceeds 30.
    • Document the prescribed regimen, including maintenance dosing of 3 mg/kg every 2 weeks for adults and pediatric patients and the applicable dose-escalation phase.

    Disease and Treatment Background

    Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disease caused by reduced acid sphingomyelinase activity due to pathogenic variants in the SMPD1 gene. The resulting sphingomyelin accumulation in tissues may produce disease manifestations including abdominal pain, vomiting, headache, urticaria, nausea, rash, arthralgia, pruritus, fatigue, and pharyngitis. Xenpozyme provides an exogenous source of acid sphingomyelinase but is not expected to cross the blood-brain barrier; its treatment scope is therefore limited to non-neurologic manifestations.

    Definitions and Calculation Rules

    Acid sphingomyelinase deficiency confirmation
    Diagnostic thresholdAcid sphingomyelinase activity less than 10% of a control sample
    Peripheral blood leukocytesAcid sphingomyelinase activity may be assessed in peripheral blood leukocytes
    Cultured skin fibroblastsAcid sphingomyelinase activity may be assessed in cultured skin fibroblasts
    Adjusted body weight
    BMI greater than 30Calculate adjusted body weight
    CalculationAdjusted body weight (kg) = (actual height in meters)² × 30
    BMI 30 or less

    Xenpozyme Initial Authorization

    Xenpozyme Initial Authorization

    Initial Xenpozyme authorization requires ALL applicable diagnostic, clinical, specialist, and dosing documentation criteria:

    Xenpozyme initial authorization

    • The member has a documented diagnosis of ASMD type A/B or type B, also known as Niemann-Pick disease.
    • Diagnostic confirmation

      • Acid sphingomyelinase enzyme deficiency is confirmed.
      • The diagnosis is confirmed by genetic testing of the SMPD1 gene.
    • Documentation confirms that Xenpozyme is not being used to treat neurologic manifestations, if present.

    Xenpozyme Continuation

    Xenpozyme Continuation

    Xenpozyme continuation therapy requires ALL of the following:

    Xenpozyme continuation requirements

    • The prescriber attests, or clinical review finds, no evidence of intolerable adverse effects or drug toxicity, including severe hypersensitivity reactions such as anaphylaxis.
    • Documentation shows a positive clinical response demonstrated by low disease activity and/or improvement in the condition's signs and symptoms.

      Examples include improvement in liver and spleen volume, pulmonary function, platelet count, and pediatric height z-scores.

    • Current weight, height, and body mass index (BMI) are documented.Within the last 30 days

      For BMI greater than 30, dosing must be based on adjusted body weight.

    Dosing and Quantity Limits

    Xenpozyme maintenance dose
    MedicationXenpozyme (olipudase alfa-rpcp)
    Maintenance dose3 mg/kg
    Administration intervalEvery 2 weeks
    PopulationAdults and pediatric patients

    Administration Site Requirements

    Note

    Use an approved non-hospital site of care

    Administer infused Xenpozyme in a non-hospital facility-based location under Molina's Site of Care Utilization Management Policy.

    • The Site of Care Utilization Management Policy applies to Xenpozyme (olipudase alfa-rpcp).
    Policy Summary
    PayerMolina Healthcare
    PolicyAcid Sphingomyelinalase Deficiency (ASMD) — Xenpozyme Coverage
    Policy CodePolicy C24670-A
    Change TypeAnnual review — no material coverage changes
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit diagnostic confirmation, non-neurologic treatment goals, and current weight, height, and BMI for Xenpozyme prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing ReferenceProvider Requirements and Review RisksDisease and Treatment BackgroundDefinitions and Calculation RulesXenpozyme Initial AuthorizationXenpozyme ContinuationDosing and Quantity LimitsAdministration Site Requirements
    Current height must be documented
    Body mass indexCurrent BMI must be documented
    Required recencyMeasurements must be obtained within the last 30 days
    BMI threshold for adjusted body weight
    Adjusted body weight appliesBMI greater than 30
    Actual body weight ruleUse actual body weight when BMI is 30 or less
    CalculationAdjusted body weight (kg) = (actual height in meters)² × 30
    Prior Authorization

    Reauthorization Requirements

    Initial and continuation authorizations are issued for 12 months. Reauthorization requires clinical review and updated documentation demonstrating that continuation remains medically necessary.

    • Initial authorization period: 12 months.
    • Continuation authorization period: 12 months.
    • For reauthorization, submit evidence of tolerability, no unacceptable toxicity, positive clinical response, and current dosing measurements obtained within the last 30 days.

    Unsupported block type: documentation

    Documentation Required

    Diagnostic Confirmation

    Confirm the covered ASMD diagnosis with acceptable laboratory or genetic evidence before requesting Xenpozyme.

    • Covered diagnosis: ASMD type A/B or type B (Niemann-Pick disease).
    • Confirm acid sphingomyelinase deficiency through enzyme activity testing or genetic testing of the SMPD1 gene.
    • ASM activity below 10% of the control sample in peripheral blood leukocytes or cultured skin fibroblasts demonstrates deficiency.
    Documentation Required

    Non-Neurologic Treatment Goals

    Document that treatment is directed only at non-neurologic manifestations of ASMD and establish individualized treatment goals tied to the member's baseline disease burden.

    • Xenpozyme is indicated for non-central nervous system manifestations and must not be used to treat neurologic manifestations.
    • Record individualized goals addressing relevant measures such as hepatosplenomegaly, liver and spleen volume, pulmonary function, platelet count, pediatric height z-scores, overall health, and quality of life.
    Documentation Required

    Recent Dosing Measurements

    Provide recent dosing measurements for every authorization request. Measurements must be obtained within the last 30 days, and dosing for BMI greater than 30 must use adjusted body weight.

    • Submit current dosing weight, actual weight, height, and BMI.
    • Use actual body weight when BMI is less than or equal to 30.
    • For BMI greater than 30, calculate adjusted body weight as (height in meters)² × 30, as specified in the policy appendix.
    Documentation Required

    Qualified Prescriber or Consultant

    Xenpozyme must be prescribed by, or in consultation with, a qualified specialist experienced in ASMD or related disorders. If prescribed in consultation, include the consultation notes with both the initial request and each reauthorization request.

    • Acceptable prescribers or consultants include a board-certified geneticist, hematologist, pulmonologist, hepatologist, pediatric metabolic specialist, or physician experienced in managing ASMD, Niemann-Pick disease, or enzyme deficiency disorders.
    • Submit consultation notes with the initial authorization request and continuation or reauthorization requests when the prescriber is relying on consultation.
    Documentation Required

    Continuation Documentation

    For continuation, attest to or document that the member is tolerating treatment without unacceptable toxicity and is demonstrating a positive clinical response. Updated weight, height, and BMI documentation is also required.

    • Document no intolerable adverse effects or drug toxicity, including no severe hypersensitivity reaction such as anaphylaxis.
    • Demonstrate positive clinical response through low disease activity and/or improvement in signs and symptoms, including relevant changes in liver or spleen volume, pulmonary function, platelet count, or pediatric height z-scores.
    • Submit current weight, height, and BMI obtained within the last 30 days and apply adjusted body weight when BMI exceeds 30.
    Documentation Required

    Liver Enzyme Monitoring

    Monitor transaminases at the required times to support safe initiation and dose escalation of Xenpozyme.

    • Assess ALT and AST within 1 month before Xenpozyme initiation.
    • During dose escalation, assess ALT and AST within 72 hours before each infusion.
    • If a dose is not administered within 3 days of the scheduled date, follow the Xenpozyme prescribing-information recommendations for missed doses.
    Denial Risk

    Contraception Counseling

    Counsel female patients of reproductive potential about fetal risk and document use of effective contraception during treatment and for 14 days after the last dose.

    • Dose initiation or escalation is not recommended at any time during pregnancy because elevated sphingomyelin metabolite levels may increase the risk of fetal malformations.
    • Document contraception counseling and the patient's plan for effective contraception during treatment and for 14 days after the final dose.
    Denial Risk

    Noncovered Indication or Inadequate Diagnostic Support

    Coverage may be denied when the requested use is not an FDA-approved non-neurologic ASMD indication or when the diagnosis is not adequately supported by required clinical, enzyme, or genetic documentation.

    • All other uses of Xenpozyme are considered experimental or investigational and follow Molina's Off-Label policy.
    • Unsupported ASMD type, absent diagnostic confirmation, or failure to document the required enzyme deficiency or SMPD1 genetic testing may result in denial.
    • Do not initiate or escalate treatment during pregnancy; such use is not recommended because of potential fetal risk.
    Denial Risk

    Missing Required Clinical Documentation

    Missing required clinical documentation may delay review, trigger additional information requests, or result in denial. Ensure that the request includes the member's treatment goals and disease measures, dosing data, and qualified provider information.

    • Include individualized non-neurologic treatment goals and baseline disease measures.
    • Include current weight, height, BMI, and the appropriate actual or adjusted dosing weight.
    • Include prescriber qualifications or required consultation notes.
    • For continuation, include clinical response, disease activity or sign-and-symptom measures, and tolerability or toxicity documentation.
    Denial Risk

    Lack of Response or Unacceptable Toxicity

    Continuation may be denied when the member has no documented positive clinical response, develops unacceptable toxicity, or experiences severe hypersensitivity. A severe hypersensitivity reaction, including anaphylaxis, requires immediate discontinuation and appropriate medical treatment.

    • Document low disease activity and/or improvement in ASMD signs and symptoms for continuation.
    • Document absence of intolerable adverse effects and drug toxicity.
    • If severe hypersensitivity occurs, discontinue Xenpozyme immediately and initiate appropriate medical treatment; re-administration requires consideration of risks and benefits.
    Billing Rule

    Improper Billing or Noncovered Benefit

    Claims may be rejected or payment recovered when billing is inappropriate or the service is not a covered benefit. Use industry-standard coding and verify benefit, site-of-care, and applicable policy requirements before administration.

    • HCPCS J0218: Injection, olipudase alfa-rpcp, 1 mg.
    • Code listings are for reference and do not guarantee coverage; deleted or inactive codes may not be reimbursable.
    • Molina may reject or deny a claim and recover payment when the service is billed incorrectly or is not a covered benefit.
    • The Site of Care Utilization Management Policy applies; infused medications are recommended for administration in a non-hospital facility-based location under the Molina site-of-care program.
    Use actual body weight
    ASMD type A/B or type B
    Covered presentationASMD type A/B or type B
    Alternate terminologyAlso known as Niemann-Pick disease
    Coverage statusThis disease presentation is identified in the coverage criteria
  1. Individualized therapeutic goals are documented based on the member's non-neurologic baseline symptoms, overall health, and quality of life.

    Examples include hepatosplenomegaly, liver and spleen volume, pulmonary function, platelet count, and pediatric height z-scores. Documentation is required.

  2. Current dosing weight, weight, height, and BMI are documented.Within the last 30 days

    For BMI greater than 30, dosing must be based on adjusted body weight.

  3. Xenpozyme is prescribed by or in consultation with a qualified specialist experienced in ASMD or related enzyme deficiency disorders.

    Qualified specialists include a board-certified geneticist, hematologist, pulmonologist, hepatologist, pediatric metabolic specialist, or physician experienced in ASMD, Niemann-Pick disease, or enzyme deficiency disorders. Consultation notes must be submitted when prescribed in consultation.